During PDAC progression, TGF-β signaling becomes hyperactive because of increased TGF-β secretion from both cancer cells and their surrounding stroma, and this activation is known to be associated with poor survival in PDAC patients (Friess et al, 1993; Bardeesy et al, 2006). The gene discussed is TGFB1; the disease is cancer.